Therapeutic angiogenesis for patients with no-option critical limb ischemia by adipose-derived regenerative cells: TACT-ADRC multicenter trial.

"Declarations Competing interestsAll authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest or non-financial interest in the subject matter or materials discussed in this manuscript. Ethical approvalAll procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was approved by the Bioethics Committee of the Nagoya University (No. NA8150011). Consent to participateInformed consent was obtained from all individual participants included in the study. Competing interests All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest or non-financial interest in the subject matter or materials discussed in this manuscript."

"Funding This study was supported, in part, by the Japanese Circulation Society Translational Research Grant 2010-13, Japan Agency for Medical Research and Development (AMED) 2014-15, and a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan (No. 26293184 to T.M.)."

"All protocols were approved by the Nagoya University certified committee for regenerative medicine (#NA8150011) and the Tokai-Hokuriku Regional Bureau of Health and Welfare, Japan. This clinical trial is registered in the UMIN Clinical Trials Registry (#UMIN000010143) and the Japan Registry of Clinical Trials (#jRCTb040190118). All adverse events were reported to the committee based on the Japan Clinical Trial Registry (#jRCTb040190118) for verification of causality and discussion and approval of whether or not to continue the study."